Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences presented updated pivotal data from the APEX trial of bezuclastinib in advanced systemic mastocytosis (AdvSM) at the EHA Congress. The drug achieved a 65% objective response rate per mIWG criteria and 81% per PPR criteria in 81 treated patients, with 91% showing ≥50% reduction in variant allele frequency.
Key figures
- Drug Name
- bezuclastinib
- Phase Of Trial
- Pivotal
- Orr ppr
- 81%
- Orr miwg
- 65%
- Os 12month
- 87%
- Pfs 12month
- 79%
- Patients treated
- 81
- Patients evaluable
- 68
- Vaf reduction ge50
- 91%
- Tryptase reduction ge50
- 89%
- Bm mast cell reduction ge50
- 89%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.